Novozymes Biopharma will showcase its bacillus-based hyaluronic acid (bHA) at the 2010 International Conference on hyaluronan, from 6-11 June in Kyoto, Japan.
The company will also introduce its first pilot cGMP-compliant sample program for this novel source of HA and will deliver a series of educational presentations.
Novozymes Biopharma's booth will feature a recombinant source of HA, produced without the use of animal-derived raw materials or organic solvents.
This approach to producing HA product is based on Novozymes Biopharma's safe fermentation and purification technology, which results in a consistent and pure product.
The production system is based on Bacillus subtilis, a well-characterised, non-pathogenic and endotoxin-free organism that is considered safe by the US Food and Drug Administration (FDA).
Novozymes Biopharma will also provide bHA pilot samples ahead of the launch of the company's Q7 cGMP compliant HA facility in Tianjin, China.
This new facility is due to come on line in the first quarter of 2011 and will be dedicated to the production of HA for medical applications.
Dr Khadija Schwach-Abdellaoui, senior research and development manager at Novozymes Biopharma, has been invited to deliver a 30-minute presentation called 'Hyacare - New Preferred Biopolymer Template for Medical Devices and Drug Delivery Systems'.
Novozymes Biopharma will also present two technical posters at the conference, demonstrating the many advantages of bHA over conventional rooster comb and Streptococcus-derived HAs.
